Bristol Myers Squibb BMY suffered a setback in the late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos (mavacamten). The phase III study was evaluating Camzyos for the treatment of ...

Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Multi-Factor Investor model based on the published ...

Wall Street expects a year-over-year increase in earnings on lower revenues when Bristol Myers Squibb (BMY) reports results for the quarter ended March 2025. While this widely-known consensus ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other dirt cheap stocks to invest in now. The stock market has been experiencing ...

We recently published a list of 10 Dirt Cheap Stocks To Invest In Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other dirt cheap ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best pharma stocks to buy for long term growth. With big American pharmaceutical ...

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology ...

The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. Karuna’s crown jewel, an ...